Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Sonelokimab in Patients with Active Psoriatic Arthritis or Axial Spondyloarthritis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment called Sonelokimab in patients with active Psoriatic Arthritis or Axial Spondyloarthritis. These are conditions that cause inflammation in the joints and spine, leading to pain and stiffness. The study aims to explore how this treatment affects the activity of these diseases.

Participants in the study will receive Sonelokimab through a subcutaneous injection, which means it is injected under the skin. Additionally, a special imaging agent called 68Ga-FAPI-46 will be used to help visualize the inflammation in the body. This agent is injected and then detected using a scan called FAPI-PET/CT, which combines positron emission tomography and low-dose computed tomography to create detailed images of the body's internal structures.

The purpose of the study is to assess changes in disease activity over a period of 12 weeks. Participants will undergo regular imaging scans to monitor the effects of the treatment. The study will help researchers understand how Sonelokimab impacts inflammation in the joints and spine, potentially leading to better treatment options for people with these conditions.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, a healthcare professional will explain the study procedures and answer any questions you may have.

    You will undergo a series of tests to confirm your eligibility for the study. These tests may include blood tests, imaging scans, and a physical examination.

  2. Step 2

    Medication administration

    If eligible, you will begin receiving the study medication, sonelokimab, through a subcutaneous injection. This means the medication will be injected under your skin.

    The dosage and frequency of the injections will be determined by the study protocol and communicated to you by the healthcare team.

  3. Step 3

    Imaging study

    Throughout the study, you will undergo imaging studies to assess the effects of the medication. This includes a FAPI-PET/CT scan, which helps visualize inflammation in your body.

    These scans will be scheduled at specific intervals, such as at the beginning and at Week 12 of the study.

  4. Step 4

    Regular follow-up visits

    You will have regular follow-up visits with the healthcare team. These visits are important to monitor your health and any changes in your condition.

    During these visits, you may be asked to complete questionnaires about your symptoms and overall well-being.

  5. Step 5

    End of study visit

    At the end of the study period, you will have a final visit. This visit will include a comprehensive assessment of your health and a review of your experience during the study.

    The healthcare team will discuss the next steps and any follow-up care that may be needed.

Who can join the trial?

19 criteria

  • Participants must be at least 18 years old.
  • For Psoriatic Arthritis (PsA) only: Must test negative for rheumatoid factor and anti-cyclic citrullinated peptide antibodies.
  • For PsA only: Must have active PsA and meet one of the following:
    • Did not respond well to at least one non-biologic conventional DMARD (a type of medication) after 12 weeks.
    • Cannot tolerate DMARDs.
    • Cannot take DMARDs due to other health reasons.
    • For Axial Spondyloarthritis (axSpA) only: Must have a diagnosis of non-radiographic axSpA with:
      • Symptoms starting before age 45.
      • Inflammatory back pain for at least 3 months.
      • Signs of disease activity on MRI or positive C-Reactive protein test.
      • For axSpA only: Must show active disease with a BASDAI score of 4 or higher, despite treatment with NSAIDs (a type of pain reliever) for at least 4 weeks.
      • For axSpA only: Must have signs of active disease on MRI within 4 weeks before screening.
      • For axSpA only: Ideally, participants should not have used biologic DMARDs or targeted synthetic DMARDs, or have used limited amounts of specific medications with appropriate wash-out periods.
      • Must have a positive FAPI-PET/CT scan, indicating high inflammatory disease activity.
      • Female participants must not be pregnant or breastfeeding and must agree to use effective birth control methods during the study and for 8 weeks after the last treatment.
      • Male participants must agree to use a condom during sexual activity with a female partner who can become pregnant, during the study and for 12 weeks after the last treatment, unless surgically sterile.
      • Participants must be reliable and able to follow the study protocol and schedule, and must provide signed informed consent.
      • For PsA only: Must have a confirmed diagnosis of PsA with symptoms for at least 3 months before screening.
      • For PsA only: Must show evidence of active disease, such as joint swelling or pain.
      • For PsA only: Must have signs of inflammation, such as enthesitis, tendinitis, synovitis, or dactylitis, confirmed by clinical investigation or imaging tests within 4 weeks before screening.
      • For PsA only: Must have current active psoriasis, nail changes due to psoriasis, or a history of psoriasis.

Who cannot join the trial?

6 criteria

  • Patients who are not diagnosed with psoriatic arthritis or axial spondyloarthritis cannot participate.
  • Patients who are not within the specified age range cannot participate.
  • Patients who are not part of the specified clinical trial group cannot participate.
  • Patients who are not willing to undergo the required imaging tests, such as FAPI-PET/CT scans, cannot participate. PET/CT scans are imaging tests that help doctors see how your tissues and organs are functioning.
  • Patients who are not able to comply with the study procedures and visits cannot participate.
  • Patients who are part of a vulnerable population, such as those unable to give informed consent, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sonelokimab is a medication being studied for its potential to help people with certain types of arthritis, specifically psoriatic arthritis and axial spondyloarthritis. These are conditions where the immune system mistakenly attacks the joints, causing pain and swelling. Sonelokimab works by targeting specific proteins in the body that are involved in the inflammation process. By blocking these proteins, the medication aims to reduce inflammation and improve symptoms in patients. In this trial, researchers are using special imaging techniques to see how well sonelokimab can reduce disease activity in the body.

What is already known about the treatment

Sonelokimab – Sonelokimab is administered through an injection, typically under the skin, which is known as a subcutaneous injection. It is currently being studied in clinical trials for its effects on conditions like psoriatic arthritis and axial spondyloarthritis. These are inflammatory diseases that affect the joints and spine, causing pain and stiffness. Sonelokimab works by targeting specific proteins in the body that are involved in the inflammation process, helping to reduce symptoms and improve joint function. It belongs to a class of medications known as biologics, which are designed to interfere with the pathways that lead to inflammation.

Investigated diseases

  • Psoriatic Arthritis

    Psoriatic arthritis is a chronic inflammatory condition that affects the joints and is associated with psoriasis, a skin disease. It typically causes joint pain, stiffness, and swelling, which can lead to joint damage over time. The disease often begins with mild symptoms and can progress to more severe joint involvement. It may affect any joint in the body, but commonly involves the fingers, toes, and spine. The progression can vary greatly among individuals, with periods of increased activity and remission. Over time, it can lead to reduced joint function and mobility.

  • Axial Spondyloarthritis

    Axial spondyloarthritis is a type of inflammatory arthritis that primarily affects the spine and the sacroiliac joints, which connect the lower spine to the pelvis. It is characterized by chronic back pain and stiffness, which can worsen over time. The disease often begins in early adulthood and can lead to reduced flexibility and mobility of the spine. As the condition progresses, it may cause the vertebrae to fuse, leading to a loss of spinal mobility. The progression of symptoms can vary, with some individuals experiencing mild symptoms and others developing more severe spinal changes. The disease can also affect other areas of the body, including the eyes and the gastrointestinal tract.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-514504-13-00Protocol codeM1095-snSpA-202Estimated enrolment30 patientsSponsorMoonLake Immunotherapeutics AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).